Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Inclusion Criteria: * 1.Male or female ≥18 and ≤70 years * 2.Meet the revised Michet criteria * 3.Patients had an inadequate response to standard treatment for ≥ 4 weeks. The background treatment included corticosteroids (≤0.5 mg/ kg), immunosuppressants ( methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil leflunomide, or cyclophosphamide) * 4\. Negative urine pregnancy test * 5\. Written informed consent form Exclusion Criteria: Any subject who meets any of the following criteria shall be excluded: * 1.Use rituximab or other monoclonal antibodies within 2 months. * 2.1 months after treatment with high dose glucocorticoid (\> 1 mg/kg/d). * 3.Serious complications: heart failure (≥ New York Heart Association（NYHA） III grade), renal insufficiency (creatinine clearance rate ≤ 30 ml/min), liver function insufficiency (serum alanine transaminase or glutamic-pyruvic transaminaseT \> 3 times normal upper limit, or total bilirubin \> normal upper limit) * 4.Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve, or brain diseases (including demyelination diseases, such as multiple sclerosis). * 5.Known allergies, hyperresponsiveness or IL-2 or its excipients are intolerant. * 6.Severe infections (including, but not limited to, hepatitis, pneumonia, bacteremia, pyelonephritis, Epstein-Barr virus, tuberculosis infection), hospitalization for infection, or intravenous antibiotics 2 months before the first dose o…